Page 1934 - Williams Hematology ( PDFDrive )

1908 Part XII: Hemostasis and Thrombosis Chapter 112: Platelet Morphology, Biochemistry, and Function 1909

1521. Retzer M, Essler M: Lysophosphatidic acid-induced platelet shape change proceeds 1554. McCloskey DJ, et al: Selective serotonin reuptake inhibitors: Measurement of effect on
via Rho/Rho kinase-mediated myosin light-chain and moesin phosphorylation. Cell platelet function. Transl Res 151(3):168–172, 2008.
Signal 12(9–10):645–648, 2000. 1555. Lesurtel M, et al: Platelet-derived serotonin mediates liver regeneration. Science
1522. Haseruck N, et al: The plaque lipid lysophosphatidic acid stimulates platelet activation 312(5770):104–107, 2006.
and platelet-monocyte aggregate formation in whole blood: Involvement of P2Y1 and 1556. Haslam RJ, Rosson GM: Aggregation of human blood platelets by vasopressin. Am J
P2Y12 receptors. Blood 103(7):2585–2592, 2004. Physiol 223(4):958–967, 1972.
1523. Olorundare OE, et al: Assembly of a fibronectin matrix by adherent platelets stimu- 1557. Pollock WK, MacIntyre DE: Desensitization and antagonism of vasopressin-induced
lated by lysophosphatidic acid and other agonists. Blood 98(1):117–124, 2001. phosphoinositide metabolism and elevation of cytosolic free calcium concentration in
1524. Maschberger P, et al: Mildly oxidized low density lipoprotein rapidly stimulates via human platelets. Biochem J 234(1):67–73, 1986.
activation of the lysophosphatidic acid receptor Src family and Syk tyrosine kinases 1558. Thomas ME, Osmani AH, Scrutton MC: Some properties of the human platelet vaso-
and Ca2+ influx in human platelets. J Biol Chem 275(25):19159–19166, 2000. pressin receptor. Thromb Res 32(6):557–566, 1983.
1525. Siess W: Athero- and thrombogenic actions of lysophosphatidic acid and sphin- 1559. Thibonnier M, Roberts JM: Characterization of human platelet vasopressin receptors.
gosine-1-phosphate. Biochim Biophys Acta 1582(1–3):204–215, 2002. J Clin Invest 76(5):1857–1864, 1985.
1526. Motohashi K, et al: Identification of lysophospholipid receptors in human platelets: 1560. Siess W, et al: Activation of V1-receptors by vasopressin stimulates inositol phos-
The relation of two agonists, lysophosphatidic acid and sphingosine 1-phosphate. pholipid hydrolysis and arachidonate metabolism in human platelets. Biochem J
FEBS Lett 468(2–3):189–193, 2000. 233(1):83–91, 1986.
1527. Siess W, Tigyi G: Thrombogenic and atherogenic activities of lysophosphatidic acid. J 1561. Thibonnier M, Goraya T, Berti-Mattera L: G protein coupling of human platelet V1
Cell Biochem 92(6):1086–1094, 2004. vascular vasopressin receptors. Am J Physiol 264(5 Pt 1):C1336–C1344, 1993.
1528. Yatomi Y, et al: Sphingosine-1-phosphate: A platelet-activating sphingolipid released 1562. Berrettini WH, et al: Human platelet vasopressin receptors. Life Sci 1982;30(5):
from agonist-stimulated human platelets. Blood 86(1):193–202, 1995. 425–432, 1993.
1529. Nugent D, Xu Y: Sphingosine-1-phosphate: Characterization of its inhibition of plate- 1563. Siess W: Molecular mechanisms of platelet activation. Physiol Rev 69(1):58–178, 1989.
let aggregation. Platelets 11(4):226–232, 2000. 1564. Wun T, Paglieroni T, Lachant NA: Physiologic concentrations of arginine vasopressin
1530. Hoyer D, et al: International Union of Pharmacology classification of receptors for activate human platelets in vitro. Br J Haematol 92(4):968–972, 1996.
5-hydroxytryptamine (Serotonin). Pharmacol Rev 46(2):157–203, 1994. 1565. Gunnet JW, et al: Pharmacological characterization of RWJ-676070, a dual vaso-
1531. Allen JA, Yadav PN, Roth BL: Insights into the regulation of 5-HT2A serotonin recep- pressin V(1A)/V(2) receptor antagonist. Eur J Pharmacol 590(1–3):333–342, 2008.
tors by scaffolding proteins and kinases. Neuropharmacology 55(6):961–968, 2008. 1566. Serradeil-Le Gal C, et al: Nonpeptide vasopressin receptor antagonists: Develop-
1532. Cook EH Jr, et al: Primary structure of the human platelet serotonin 5-HT2A receptor: ment of selective and orally active V1a, V2 and V1b receptor ligands. Prog Brain Res
Identify with frontal cortex serotonin 5-HT2A receptor. J Neurochem 63(2):465–469, 1994. 139:197–210, 2002.
1533. De Clerck F, et al: Evidence for functional 5-HT2 receptor sites on human blood plate- 1567. Crabos M, Bertschin S, Bühler FR, et al: Identification of AT1 receptors on human
lets. Biochem PharmacolAm Rev Respir Dis 33(17):2807–2811, 1984. platelets and decreased angiotensin II binding in hypertension. J Hypertens Suppl 11
1534. Roth BL, et al: 5-Hydroxytryptamine2-family receptors (5-hydroxytryptamine2A, Suppl 5:S230–S231, 1993.
5- hydroxytryptamine2B, 5-hydroxytryptamine2C): Where structure meets function. 1568. Jagroop IA, Mikhailidis DP: Angiotensin II can induce and potentiate shape change in
Pharmacol Ther 79(3):231–257, 1998. human platelets: Effect of losartan. J Hum Hypertens 2000;14(9):581–585, 1993.
1535. Leysen JE, et al: Identification of nonserotonergic [3H]ketanserin binding sites associ- 1569. Lopez-Farre A, et al: Angiotensin II AT(1) receptor antagonists and platelet activa-
ated with nerve terminals in rat brain and with platelets; relation with release of biogenic tion. Nephrol Dial Transplant 16 Suppl 1:45–49, 2001.
amine metabolites induced by ketans. J Pharmacol Exp Ther 244(1):310–321, 1988. 1570. Larsson PT, Schwieler JH, Wallen NH: Platelet activation during angiotensin II infu-
1536. Ozaki N, et al: A naturally occurring amino acid substitution of the human serotonin sion in healthy volunteers. Blood Coagul Fibrinolysis 11(1):61–69, 2000.
5- HT2A receptor influences amplitude and timing of intracellular calcium mobiliza- 1571. Li P, et al: Novel angiotensin II AT(1) receptor antagonist irbesartan prevents throm-
tion. J Neurochem 68(5):2186–2193, 1997. boxane A(2)-induced vasoconstriction in canine coronary arteries and human plate-
1537. Shimizu M, et al: Serotonin-2A receptor gene polymorphisms are associated with let aggregation. J Pharmacol Exp Ther 292(1):238–246, 2000.
serotonin-induced platelet aggregation. Thromb Res 112(3):137–142, 2003. 1572. Monton M, et al: Comparative effects of angiotensin II AT-1-type receptor antagonists
1538. Arora RC, Meltzer HY: Serotonin2 receptor binding in blood platelets of schizo- in vitro on human platelet activation. J Cardiovasc Pharmacol 35(6):906–913, 2000.
phrenic patients. Psychiatry Res 47(2):111–119, 1993. 1573. Kalinowski L, et al: Angiotensin II AT1 receptor antagonists inhibit platelet adhesion
1539. Coccaro EF, et al: Impulsive aggression in personality disorder correlates with platelet and aggregation by nitric oxide release. Hypertension 40(4):521–527, 2002.
5- HT2A receptor binding. Neuropsychopharmacology 16(3):211–216, 1997. 1574. Jimenez AM, et al: Inhibition of platelet activation in stroke-prone spontaneously
1540. Pandey GN: Altered serotonin function in suicide. Evidence from platelet and neu- hypertensive rats: Comparison of losartan, candesartan, and valsartan. J Cardiovasc
roendocrine studies. Ann N Y Acad Sci 836:182–200, 1997. Pharmacol 37(4):406–412, 2001.
1541. Tomiyoshi R, et al: Serotonin-induced platelet intracellular Ca2+ responses in 1575. Owens P, et al: Comparison of antihypertensive and metabolic effects of losartan and
untreated depressed patients and imipramine responders in remission. Biol Psychiatry losartan in combination with hydrochlorothiazide—A randomized controlled trial. J
45(8):1042–1048, 1999. Hypertens 18(3):339–345, 2000.
1542. Wolfe BE, Metzger E, Jimerson DC: Research update on serotonin function in bulimia 1576. Schieffer B, et al: Comparative effects of AT1-antagonism and angiotensin-converting
nervosa and anorexia nervosa. Psychopharmacol Bull 33(3):345–354, 1997. enzyme inhibition on markers of inflammation and platelet aggregation in patients
1543. Cho R, et al: Relationship between central and peripheral serotonin 5-HT2A recep- with coronary artery disease. J Am Coll Cardiol 44(2):362–368, 2004.
tors: A positron emission tomography study in healthy individuals. Neurosci Lett 1577. Serebruany VL, et al: Valsartan inhibits platelet activity at different doses in mild
261(3):139–142, 1999. to moderate hypertensives: Valsartan Inhibits Platelets (VIP) trial. Am Heart J
1544. Schins A, et al: Increased coronary events in depressed cardiovascular patients: 151(1):92–99, 2006.
5-HT2A receptor as missing link? Psychosom Med 65(5):729–737, 2003. 1578. Yamada K, Hirayama T, Hasegawa Y: Antiplatelet effect of losartan and telmisartan in
1545. de Chaffoy de Courcelles D, Leysen JE, De Clerck F, et al: Evidence that phospholipid patients with ischemic stroke. J Stroke Cerebrovasc Dis 16(5):225–231, 2007.
turnover is the signal transducing system coupled to serotonin-S2 receptor sites. J Biol 1579. Dorahy DJ, et al: Stimulation of platelet activation and aggregation by a carboxyl-
Chem 260(12):7603–7608, 1985. terminal peptide from thrombospondin binding to the integrin-associated protein
1546. Erne P, Pletscher A: Rapid intracellular release of calcium in human platelets by stim- receptor. J Biol Chem 272(2):1323–1330, 1997.
ulation of 5-HT2-receptors. Br J Pharmacol 84(2):545–549, 1985. 1580. Lindberg FP, et al: Molecular cloning of integrin-associated protein: An immunoglob-
1547. Li N, et al: Effects of serotonin on platelet activation in whole blood. Blood Coagul ulin family member with multiple membrane-spanning domains implicated in alpha
Fibrinolysis 8(8):517–523, 1997. v beta 3-dependent ligand binding. J Cell Biol 123(2):485–496, 1993.
1548. Houston DS, Shepherd JT, Vanhoutte PM: Aggregating human platelets cause direct 1581. Wang XQ, Frazier WA: The thrombospondin receptor CD47 (IAP) modulates and
contraction and endothelium- dependent relaxation of isolated canine coronary associates with alpha2 beta1 integrin in vascular smooth muscle cells. Mol Biol Cell
arteries. Role of serotonin, thromboxane A2, and adenine nucleotides. J Clin Invest 9(4):865–874, 1998.
78(2):539–544, 1986. 1582. Frazier WA, et al: The thrombospondin receptor integrin-associated protein (CD47)
1549. Golino P, et al: Mediation or reocclusion by thromboxane A2 and serotonin after functionally couples to heterotrimeric Gi. J Biol Chem 274(13):8554–8560, 1999.
thrombolysis with tissue-type plasminogen activator in a canine preparation of coro- 1583. Chung J, Gao AG, Frazier WA: Thrombospondin acts via integrin-associated protein
nary thrombosis. Circulation 77:678–684, 1988. to activate the platelet integrin alphaIIbbeta3. J Biol Chem 272(23):14740–14746,
1550. Alberio LJ, Clemetson KJ: All platelets are not equal: COAT platelets. Curr Hematol 1997.
Rep 3(5):338–343, 2004. 1584. Isenberg JS, et al: Thrombospondin-1 stimulates platelet aggregation by blocking
1551. Dale GL, et al: Stimulated platelets use serotonin to enhance their retention of proco- the antithrombotic activity of nitric oxide/cGMP signaling. Blood 111(2):613–623,
agulant proteins on the cell surface. Nature 415(6868):175–179, 2002. 2008.
1552. Walther DJ, et al: Serotonylation of small GTPases is a signal transduction pathway 1585. Lagadec P, et al: Involvement of a CD47-dependent pathway in platelet adhesion on
that triggers platelet alpha-granule release. Cell 115(7):851–862, 2003. inflamed vascular endothelium under flow. Blood 101(12):4836–4843, 2003.
1553. Carneiro AM, et al: Interactions between integrin alphaIIbbeta3 and the serotonin 1586. Pimanda JE, et al: The von Willebrand factor-reducing activity of thrombospondin-1
transporter regulate serotonin transport and platelet aggregation in mice and humans. is located in the calcium-binding/C-terminal sequence and requires a free thiol at
J Clin Invest 118(4):1544–1552, 2008. position 974. Blood 100(8):2832–2838, 2002.

Kaushansky_chapter 112_p1829-1914.indd 1909 17/09/15 3:30 pm